Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 8/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29814719 | 0.77 | HTR2A (0.37) | HTR2CHTR2A | |
| SCHEMBL23089359 | 0.77 | HTR2A (0.37) | HTR2CHTR2A | |
| SCHEMBL30454060 | 0.75 | HTR2C (0.51) | SIGMAR1HTR2CPIM1PIM3PIM2 | |
| SCHEMBL5341889 | 0.75 | HTR2C (0.51) | SIGMAR1HTR2CPIM1PIM3PIM2 | |
| SCHEMBL29352233 | 0.75 | HTR6 (0.44) | SIGMAR1HTR2CHTR6HTR2AQDPR | |
| Hydrochloric Acid SCHEMBL30541475 | 0.75 | HTR6 (0.44) | SIGMAR1HTR2CHTR6HTR2AQDPR | |
| SCHEMBL14761633 | 0.74 | CDK9 (0.57) | SIGMAR1HTR2CPIM1PIM3PIM2 | |
| SCHEMBL3453255 | 0.74 | HTR2C (0.51) | SIGMAR1HTR2CPIM1PIM3PIM2 | |
| SCHEMBL7940586 | 0.74 | SIGMAR1 (0.49) | SIGMAR1HTR2CPIM1PIM3PIM2 | |
| SCHEMBL13490658 | 0.74 | SIGMAR1 (0.49) | SIGMAR1HTR2CPIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2576520-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| EP-2426120-A1 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | Fujifilm Finechemicals Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | SIGMAR1 1466/4885HTR2C 399/4885HTR6 124/4885 |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | QDPR, HRH4, HRH2 | SIGMAR1 1270/4885HTR2C 391/4885HTR6 110/4885 |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | SIGMAR1 71/4885HTR2C 10/4885HTR6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.